Page last updated: 2024-12-06

americium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Americium (Am) is a synthetic actinide element, not found naturally, produced in nuclear reactors through neutron bombardment of plutonium. It is a silvery-white radioactive metal with a variety of isotopes, some with long half-lives. Due to its radioactivity, americium poses health risks and is used in smoke detectors, medical imaging, and neutron sources, its unique nuclear properties being of great interest to scientists. It is also studied for its potential use in power generation and nuclear waste management.'

Americium: A completely man-made radioactive actinide with atomic symbol Am, and atomic number 95. Its valence can range from +3 to +6. Because of its nonmagnetic ground state, it is an excellent superconductor. It is also used in bone mineral analysis and as a radiation source for radiotherapy. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23966
CHEBI ID33389
MeSH IDM0000896

Synonyms (22)

Synonym
americium
americio
CHEBI:33389
amerizium
95am
americium atom
7440-35-9
AM ,
D000576000
hsdb 7383
americium, radioactive
unii-vw92phu2uy
einecs 231-144-4
vw92phu2uy ,
americium(iii)
americium, ion(3+)
americium, elemental
americium [mi]
DTXSID3064693
americium ion
americium(3+)
Q1872

Research Excerpts

Overview

Americium is a man-made metal produced in very small quantities in nuclear reactors.

ExcerptReferenceRelevance
"Americium is a man-made metal produced in very small quantities in nuclear reactors. "( Americium Inhalational Exposure with Successful Chelation Therapy.
Behrens, T; Bowen, A; Bravenec, S; Davis, J; Goans, R; Iddins, C; Keenan, M, 2022
)
3.61

Toxicity

ExcerptReferenceRelevance
" The paper suggests a relatively safe body chemical composition analyser (BCCA) machine that uses a spherical Pb shield, enclosing the neutron source."( Improving the safety of a body composition analyser based on the PGNAA method.
Izadi-Najafabadi, R; Miri-Hakimabad, H; Panjeh, H; Vejdani-Noghreiyan, A, 2007
)
0.34
" Toxic soils occupy 26% of the territory."( [The assessment of radionuclide contamination and toxicity of soils sampled from "experimental field" site of Semipalatinsk nuclear test site].
Belykh, ES; Evseeva, TI; Geras'kin, SA; Kriazheva, EIu; Maĭstrenko, TA,
)
0.13
" The study suggests an approach to evaluation of non-toxic and toxic stages under conditions of chronic radioactive exposure."( Effect of low-dose ionizing radiation on luminous marine bacteria: radiation hormesis and toxicity.
Kudryasheva, NS; Rozhko, TV, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" The 238Pu was apparently cleared with a biological half-life of approximately 800 days, predominantly by systemic or lymphatic uptake, with at least part of the translocated material being subsequently deposited in bone."( Differential clearance of plutonium and americium oxides from the human lung.
Eakins, JD; Newton, D; Taylor, BT, 1983
)
0.53

Bioavailability

ExcerptReferenceRelevance
" The investigation of low specific-activity environmental or industrial materials, and the very low bioavailability of elements such as the actinides, means that very low levels of activity have to be measured."( Measurements of the gastrointestinal absorption and tissue distribution of plutonium, americium and polonium in experimental animals.
Bonas, HE; Haines, JW; Harrison, JD; Naylor, GP; Whysall, K, 1993
)
0.51
" In addition, after confirming that most of the contamination is present in particulate form, some bioavailability laboratory-based experiments, based on the use of single extractants, were performed as an essential step in order to study the behaviour of the Pu contamination in the soils from the affected areas."( Levels, distribution and bioavailability of transuranic elements released in the Palomares accident (Spain).
García León, M; García-Tenorio, R; Jiménez-Ramos, MC; Vioque, I, 2008
)
0.35
" The bioavailability of PACAs can be improved by the addition of differing lengths of alkyl side chains that alter amphipathic properties."( Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation.
Bowman, BM; Miller, SC; Wang, X, 2010
)
0.36
" Because DTPA is a highly ionized molecule with permeability-limited bioavailability, the penta-ethyl ester prodrug of DTPA is under evaluation as an orally bioavailable radionuclide decorporation agent."( Physicochemical characterization of a prodrug of a radionuclide decorporation agent for oral delivery.
Fitzsimmons, JM; Jay, M; Sadgrove, MP; Sueda, K, 2012
)
0.38
"Diethylenetriaminepentaacetic acid (DTPA) is an effective decorporation agent to facilitate the elimination of radionuclides from the body, but its permeability-limited oral bioavailability limits its utility in mass-casualty emergencies."( Orally administered DTPA penta-ethyl ester for the decorporation of inhaled (241)Am.
Doyle-Eisele, M; Guilmette, RA; Huckle, JE; Jay, M; Leed, MG; Sadgrove, MP; Sueda, K; Weber, WM, 2014
)
0.4
" A simple test has been designed to predict the bioavailability of different actinide forms likely to be found after dissemination of radioactive elements by dispersal devices or nuclear reactor incidents."( Forecasting the In Vivo Behavior of Radiocontaminants of Unknown Physicochemical Properties Using a Simple In Vitro Test.
Angulo, JF; Coudert, S; Griffiths, NM; Laroche, P; Moureau, A; Van der Meeren, A, 2016
)
0.43
" We developed an in vitro acellular assay to predict in vivo bioavailability of actinides and improve medical handling of the victims."( A quick and simple in vitro assay to predict bioavailability of actinides following accidental exposure.
Angulo, JF; Bohand, S; Griffiths, NM; Van der Meeren, A, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" At a dosage of 30 mumol kg-1, 3,4,3-LIHOPO was less effective owing to the higher retention of Pu in the liver."( The efficacies of 3,4,3-LIHOPO and DTPA for enhancing the excretion of plutonium and americium from the rat: comparison with other siderophore analogues.
Bailly, T; Burgada, R; Ellender, M; Gray, SA; Hodgson, A; Leroux, YG; Moody, JC; Pearce, M; Stradling, GN; Wilson, I, 1992
)
0.51
" Although the incidence of bone neoplasia was high among the dogs in these studies, the risk of liver tumors, especially in the Am-treated animals, exceeded that of the skeleton in some of the lower dosage levels where the survival times were long."( Plutonium- or americium-induced liver tumors and lesions in beagles.
Angus, W; Hahn, FF; Lloyd, RD; Mays, CW; Miller, SC; Shabestari, L; Taylor, GN, 1991
)
0.64
" With early treatment and at the dosage used clinically for the decorporation of actinides with DTPA (30 mumol/kg body weight) LICAM(C) was superior to DFOA but when compared with DTPA, the effect of LICAM(C) on 238Pu was greater only in bone; as little as 1 mumol LICAM(C)/kg was as effective as 30 mumol DTPA/kg."( Chelation therapy of incorporated plutonium-238 and americium-241: comparison of LICAM(C), DTPA and DFOA in rats, hamsters and mice.
Volf, V, 1986
)
0.52
" This paper reports the use of internal microdosimetry techniques to reinvestigate the dosimetry to two very similar experiments with apparently contradictory dose-response results."( The microdosimetry of lymphocytes irradiated by alpha-particles.
Fisher, DR; Harty, R, 1982
)
0.26
"This study has examined the efficacy of ZnDTPA administered in drinking water for removing 238Pu and 241Am from the rat after their simultaneous inhalation as nitrates; the dosage used was 95 mumol kg-1d-1."( Removal of inhaled plutonium and americium from the rat by administration of ZnDTPA in drinking water.
Ellender, M; Gray, SA; Hodgson, A; Moody, JC; Pearce, M; Stradling, GN; Wilson, I, 1993
)
0.57
"06% of the injected dosage per gram."( 241Am-induced thyroid lesions in the beagle.
Bruenger, FW; Lloyd, RD; Miller, SC; Taylor, GN, 1993
)
0.29
"To evaluate by the fluorescent in-situ hybridization (FISH) technique the dose-response and intercellular distribution of alpha-particle-induced chromosome aberrations."( Effect of americium-241 alpha-particles on the dose-response of chromosome aberrations in human lymphocytes analysed by fluorescence in situ hybridization.
Barquinero, JF; Schmid, E; Stephan, G, 2004
)
0.73
" No reliable dependence of cincacine efficacy on dosage has been revealed."( [Potency of peroral and parenteral administration of Zinc-DTPA for decorporation of 241Am from the gastrointestinal tract].
Il'in, LA; Ivannikov, AT; Parfenova, IM; Popov, BA; Zhorova, ES,
)
0.13
"Effect of long-term (during 4 weeks) cincacine administration following single parenteral 241Am intake has been studied on rats depending on method (per oral or parenteral), dosage and time of treatment initiation."( [Study of effectiveness of long-term per oral and parenteral cincacine administration at parenteral 241Am incorporation into the organism].
Il'in, LA; Parfenova, IM; Popov, BA; Zhorova, ES,
)
0.13
" Dose-response efficacy profiles in mice were established for the removal of intravenously injected (238)Pu and (241)Am after parenteral and oral treatment with these chelators."( Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.
Abergel, RJ; An, D; Bunin, DI; Chang, PY; Doppalapudi, RS; Jarvis, EE; Kullgren, B; Riccio, ES, 2013
)
0.39
" Simple aberrations showed linear dose-response relationships with doses."( Complex aberrations in lymphocytes exposed to mixed beams of (241)Am alpha particles and X-rays.
Brehwens, K; Czub, J; Deperas-Kaminska, M; Haghdoost, S; Staaf, E; Wojcik, A, 2013
)
0.39
" Daily dosing of 200 mg/kg/day for 10 days was well tolerated in dogs."( Orally administered DTPA di-ethyl ester for decorporation of (241)Am in dogs: Assessment of safety and efficacy in an inhalation-contamination model.
Agha, BJ; Doyle-Eisele, M; Guilmette, RA; Huckle, JE; Jay, M; Leed, MG; Mumper, RJ; Pacyniak, E; Sadgrove, MP; Susick, RL; Weber, WM, 2015
)
0.42
" Dose-response was characterized for standard and Gd-infused PAGAT polymer gel dosimeters by means of optical transmission/absorbance."( Feasibility of dose enhancement assessment: Preliminary results by means of Gd-infused polymer gel dosimeter and Monte Carlo study.
Chacón, D; Figueroa, RG; Guillen, Y; Santibáñez, M; Valente, M, 2018
)
0.48
" These observations were very encouraging, as this nanomedicine could lead to a reduction in the dosing frequency required to achieve the decorporation efficacy of unformulated 3,4,3-LI(1,2-HOPO) itself."( ENCAPSULATED 3,4,3-LI(1,2-HOPO) IN CHITOSAN NANOPARTICLES FOR DECORPORATION VIA INHALATION.
Abergel, RJ; Chen, S; Ko, R; Lai, EPC; Li, C; Wyatt, H, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
actinoid atom
f-block element atom
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (1,118)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990521 (46.60)18.7374
1990's126 (11.27)18.2507
2000's161 (14.40)29.6817
2010's259 (23.17)24.3611
2020's51 (4.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.89 (24.57)
Research Supply Index7.11 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index140.61 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (77.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews14 (1.14%)6.00%
Case Studies41 (3.34%)4.05%
Observational0 (0.00%)0.25%
Other1,172 (95.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]